Banner for American Society of Hematology 2022 meeting (ASH 2022)

In December, a contingent of our real-world data experts attended the 2022 Annual Meeting of the American Society of Hematology. Led by Chief Scientific Officer Jeffrey Brown and Senior Vice President, TriNetX Oncology GmbH Lenka Kellerman, our team spent their time at ASH 2022 advising, sharing, and learning.

Beyond these thought leaders, TriNetX data made crucial contributions to several papers and poster abstracts. Our user community, comprised of clinicians, researchers, and drug developers from around the world, continues its track record of ground-breaking work. Their insights inform how we understand and treat today’s patients, and develop safer, more effective, and more personalized therapies for tomorrow’s.

Below are summaries and links to the TriNetX-enabled research presented at ASH 2022. Contact us to learn how you can leverage the power of EHR, registry, claims, and chart review data to make your contribution to next year’s meeting.

Hip Replacement Surgery and Anticoagulation; A Mortality, Transfusion Need and Venous Thromboembolism Rate Analysis with TriNetx

Mario Rodríguez-Rodríguez, MD, Nerea Castro-Quismondo, MD, Denis Zafra-Torres, MD, Alberto Blanco-Sánchez, MD, Gema Hernandez-Ibarburu, PhD, Miguel Pedrera-Jimenez, Data Science, Rosa Ayala and Joaquín Martínez-Lopez, MD, PhD

Hip replacement surgery is usually performed in elderly patients and may lead to complications such as major bleeding and venous thromboembolism (VTE). Also, there is a higher proportion of anticoagulated patients within the elderly. Classically, vitamin K antagonists (VKA) have been associated with higher risk of bleeding and with other perioperative and post-operative complications. The aim of this study is to analyse and compare the mortality, the blood transfusion needs and the VTE rate in patients anticoagulated with VKA and in patients treated with direct oral anticoagulants (DOACs) who went through hip replacement surgery. [Read more]

Reproductive Health Needs in Patients with Bleeding Disorders

Divyaswathi Citla Sridhar, MD, Robert F. Sidonio, Jr., MD, MSc and Sanjay Ahuja, MD

The U.S. Supreme Court’s ruling to overturn Roe v. Wade may impact access to high quality reproductive healthcare for women across the United States. This includes women with bleeding disorders as well, potentially increasing the need for illegal abortions while increasing the risk of bleeding with higher rates of complications. This study aims to assess and establish the prevalence of surgical and medical abortions, including bleeding complications and utilization of emergency contraception in persons with bleeding disorders. [Read more]

Retrospective Comparison of Patients with Chronic Lymphocytic Leukemia Receiving BTK Inhibitors Versus Obinutuzumab/Venetoclax As Frontline Therapy

Jiasheng Wang, MD, Srilatha Dasari, MD, Michael Daunov, DO, Kanithra Sekaran, MD, Yeseong Kim, MD and Brenda W. Cooper, MD

Bruton tyrosine kinase inhibitors (BTKi) and fixed-duration obinutuzumab/venetoclax (OBIN/VEN) have evolved as the standard-of-care frontline treatments for patients with chronic lymphocytic leukemia (CLL). However, few studies have compared their efficacy and safety. The phase 3 randomized, non-inferiority trial, CLL17, which compares ibrutinib with OBIN/VEN and VEN/ibrutinib, is currently recruiting. However, real-world evidence is lacking. [Read more]

Differences in Light Chain (AL) Amyloidosis Epidemiology By Race and Ethnicity

Ashima Singh, PhD, MS, Aniko Szabo, PhD, Qinghua Lian, Purushottam Laud, MD, Liliana Pezzin and Anita D’Souza, MD, MS

Light chain (AL) amyloidosis is a hematologic neoplasm often diagnosed late after a prolonged course associated with multiple clinical diagnoses (referred to as precursor diagnoses in this abstract) prior to its diagnosis. There is limited information on the epidemiology of AL amyloidosis and its natural history among underrepresented groups. We sought to investigate differences in presentation and co-occurrence of various precursor diagnoses among patients with AL amyloidosis by race and ethnicity. [Read more]

Real-World Evidence of Incidence and Outcomes of Aplastic Anemia Following Administration of Immune Checkpoint Inhibitors

Srilatha Dasari, MD, William Tse, MD and Jiasheng Wang, MD

Immune checkpoint inhibitors (ICIs) have been increasingly used in both solid and hematologic malignancies. In accordance with the mechanism of ICIs, they are associated with a spectrum of autoimmune toxicities termed immune-related adverse events (irAEs), including the poorly studied immune-related hematologic toxicity. Autoimmune destruction of hematopoietic stem cells is a common pathway for most cases of sporadic aplastic anemia (AA). However, few studies have investigated the incidence and outcomes of AA following ICI use. [Read more]

Post-Transplant Lymphoproliferative Disorder after Solid Organ Transplant: From Epidemiology to Survival Outcomes from 2000 – 2022

Supreet Kaur, MD, Pankil Shah, MD PhD, Adolfo Enrique Diaz Duque, MD and Dimpy P. Shah, MD, PhD

Post-transplant lymphoproliferative disorders (PTLD) are a heterogenous group of various lymphoproliferative disorders arising after organ transplant. With the advances seen in transplant medicine, the use of solid organ transplant (SOT) and allotransplant have risen in the past decade and thus the incidence of PTLD. Prior studies have shown that patients with SOT are at 2-5-fold higher risk of developing a cancer than general population. PTLD is the most common malignancy after skin cancer in SOT patients and the most common cause of cancer related mortality amongst them. Herein, we describe the incidence, treatment pathways, and survival outcomes of PTLD arising from various SOT. [Read more]